Clinical Development Program Appropriate for Rolling BLA . Submission Expected by the End of 2025. CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Na ...
NEW YORK, 15 déc. 2025 (GLOBE NEWSWIRE) -- Cellectis (la « Société ») (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'éditio ...
The Tribunal ruled on a partial termination of the License Agreement with respect to product UCART19 V1 (also referred to as “ALLO-501” by Allogene) and provided that Cellectis shall, at Allogene’s ...
BioSyent has repurchased and cancelled a total of 3,112,525 Shares under NCIBs between December 10, 2018 and December 15, 2025 at an average price of $7.14 per Share. During the most recent NCIB, ...
Conference call and webcast to be held at 8 a.m. ET on December 16, 2025 ...
CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on ...
Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) ...
Complete financial results are included in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2025, which has been filed with the U.S. Securities and Exchange ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback